Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma Apr 13, 2022
Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Apr 04, 2022
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Apr 04, 2022
Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities Apr 04, 2022
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022 Apr 01, 2022
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights Mar 28, 2022
